Pfizer Oncology Together TM Image

Financial Assistance Resources

At Pfizer Oncology Together™, we treat your individual needs as a priority. We’ll help you identify financial assistance options so you can get your prescribed TALZENNA. We can also connect you with a dedicated Care Champion who has social work experience and will offer resources that may help with some of your day-to-day challenges. Because when it comes to support, we’re in this together.

Commercially Insured

  • Resources for eligible commercial, private, employer, and state health insurance marketplace patients:

    Co-pay assistance

    Eligible, commercially insured patients may pay as little as $0 per month for TALZENNA.* There are no income requirements, forms, or faxing to enroll.

    Sign Up

  • Co-Pay Savings Card

*Limits, terms, and conditions apply. Patients are not eligible to use this card if they are enrolled in a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veterans Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico. Patients may receive up to $25,000 per product in savings annually. The offer will be accepted only at participating pharmacies. This offer is not health insurance. No membership fees apply. Pfizer reserves the right to rescind, revoke or amend this offer without notice. For any questions, please call 1-877-744-5675, visit PfizerOncologyTogether.com/terms or write: Pfizer Oncology Together Co-Pay Savings Program, 2250 Perimeter Park Drive, Suite 300, Morrisville, NC 27560.

Medicare/government Insured

Help identifying resources for eligible patients with Medicare/Medicare Part D, Medicaid, and other government insurance plans:

  • Assistance with searching for support from independent charitable foundations: These foundations exist independently of Pfizer and have their own eligibility criteria and application processes. Availability of support from the foundations is determined solely by the foundations
  • Financial assistance through Extra Help, a Medicare Part D Low-Income Subsidy (LIS) program
  • Free medicine†

†If support from independent charitable foundations or Medicare Extra Help is not available, Pfizer Oncology Together will provide eligible patients with medication for free through the Pfizer Patient Assistance Program. The Pfizer Patient Assistance Program is a joint program of Pfizer Inc. and the Pfizer Patient Assistance Foundation™. The Pfizer Patient Assistance Foundation is a separate legal entity from Pfizer Inc. with distinct legal restrictions.

Uninsured

Help identifying resources for eligible patients without any form of healthcare coverage:

  • Help finding coverage
  • Free medicine through the Pfizer Patient Assistance Program,‡ or at a savings through the Pfizer Savings Program§

‡The Pfizer Patient Assistance Program is a joint program of Pfizer Inc. and the Pfizer Patient Assistance FoundationTM. The Pfizer Patient Assistance Foundation is a separate legal entity from Pfizer Inc. with distinct legal restrictions. §The Pfizer Savings Program is not health insurance. For more information, call the toll-free number 1-877-744-5675. There are no membership fees to participate in this program. Estimated savings are 50% and depend on such factors as the particular drug purchased, amount purchased, and the pharmacy where purchased.

CARE CHAMPION SUPPORT

At Pfizer Oncology Together, our Care Champions, who have social work experience, can provide you resources that may help with some of your day-to-day challenges*:

EMOTIONAL SUPPORT

  • We can connect you to diagnosis-specific support groups, an independent organization that offers short-term counseling, and a free app, developed by Pfizer Oncology, to help patients connect with loved ones and ask for the support they need.

EDUCATIONAL SUPPORT

  • To help support your overall health and well-being, we’ve created resources about physical and mental health, as well as nutrition tips and healthy recipes developed in partnership with dietitians who specialize in oncology nutrition. We can also provide you with information to help you understand your prescribed TALZENNA.

PRACTICAL SUPPORT

  • If you need assistance with transportation or lodging for treatment-related appointments, we’ll connect you to independent organizations that offer these services for free to qualifying patients.
  • And if you’re leaving work for a period of time during treatment, or preparing to return to work, we can send you information to help make the transition easier.

*Some services are provided through third-party organizations that operate independently and are not controlled by Pfizer. Availability of services and eligibility requirements are determined solely by these organizations.

Pfizer oncology desktop image
Pfizer oncology mobile image

Useful Resource and Links

A diagnosis of metastatic breast cancer (MBC) can be difficult, but you don't have to face it alone. Find practical and emotional support that can help you navigate your diagnosis and treatment.

Resource

Patient Brochure image

Patient Brochure

Want a comprehensive overview of TALZENNA? Download and print out this brochure.

View Full Prescribing Information

Download

Links

BreastCancer.org

BreastCancer.org

FORCE: Facing Our Risk of Cancer Empowered

FacingOurRisk.org

Living Beyond Breast Cancer

LBBC.org

METAVIVOR

Metavivor.org

SHARSHERET

Sharsheret.org

National Society of Genetic Counselors

NSGC.org

These websites are neither owned nor controlled by Pfizer. Pfizer does not endorse and is not responsible for the content or services of these sites.

Important Safety Information and Indication

View More

Important Safety Information

TALZENNA may cause serious side effects, including:

Bone marrow problems called Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML). Some people who have cancer and who have received previous treatment with chemotherapy or certain other medicines for their cancer have developed MDS or AML during or after treatment with TALZENNA. MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop treatment with TALZENNA.

Symptoms of low blood cell counts are common during treatment with TALZENNA, but can be a sign of serious problems, including MDS or AML. Tell your healthcare provider if you have any of the following symptoms during treatment with TALZENNA:

  • weakness
  • weight loss
  • fever
  • frequent infections
  • blood in urine or stool
  • shortness of breath
  • feeling very tired
  • bruising or bleeding more easily

Your healthcare provider will do blood tests to check your blood cell counts:

  • every month during treatment with TALZENNA
  • weekly if you have low blood cell counts that last a long time. Your healthcare provider may stop treatment with TALZENNA until your blood cell counts improve.

Before taking TALZENNA, tell your healthcare provider about all of your medical conditions, including if you:

  • have kidney problems
  • are pregnant or plan to become pregnant. TALZENNA can harm your unborn baby, and may cause loss of pregnancy (miscarriage). You should not become pregnant during treatment with TALZENNA. Tell your healthcare provider right away if you are pregnant or become pregnant during treatment with TALZENNA.
    • Females who are able to become pregnant should use effective birth control (contraception) during treatment with TALZENNA and for at least 7 months after receiving the last dose of TALZENNA. Talk to your healthcare provider about forms of birth control that may be right for you.
    • Males with female partners who are pregnant or are able to become pregnant should use effective birth control during treatment with TALZENNA and for at least 4 months after receiving the last dose of TALZENNA.
  • are breastfeeding or plan to breastfeed. It is not known if TALZENNA passes into your breast milk. Do not breastfeed during treatment with TALZENNA and for at least 1 month after receiving the last dose of TALZENNA. Talk to your healthcare provider about the best way to feed your baby during this time.

Tell your healthcare provider about all the medicines you take, including prescription medicines, over-the-counter medicines, vitamins, and herbal supplements. Taking TALZENNA and certain other medicines can affect how TALZENNA works and may cause side effects.

Know the medicines you take. Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get a new medicine.

How to take TALZENNA

  • Take TALZENNA exactly as your healthcare provider tells you.
  • If you miss a dose of TALZENNA or vomit, take your next dose at your regular time. Do not take an extra dose to make up for a missed dose.
  • If you take too much TALZENNA, call your healthcare provider or go to the nearest hospital emergency room right away.

The most common side effects of TALZENNA include:

  • low red blood cell counts
  • low white blood cell counts
  • low platelet counts
  • tiredness or weakness
  • increased blood glucose levels
  • increased liver function tests
  • low calcium in the blood
  • nausea
  • headache
  • vomiting
  • hair loss
  • diarrhea
  • decreased appetite

TALZENNA may cause fertility problems in males. This may affect your ability to father a child. Talk to your healthcare provider if this is a concern for you. These are not all of the possible side effects of TALZENNA.

Call your doctor for medical advice about side effects.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Indication

TALZENNA is a prescription medicine used:

  • alone to treat adults with a certain type of breast cancer (human epidermal growth factor receptor 2 [HER2]-negative)
    • who have an abnormal inherited BRCA gene, and
    • whose cancer has spread to other parts of the body (locally advanced or metastatic).

Your healthcare provider will perform a test to make sure that TALZENNA is right for you. It is not known if TALZENNA is safe and effective in children.

Please see Full Prescribing Information and Patient Information.